The unblinding of phase 3 trial data of SynCore Biotechnology Co Ltd’s (杏國新藥) newly developed pancreatic cancer drug SB05PC showed no statistical significance when compared with the control group, the drugmaker said yesterday.
SB05PC is designed to prolong patients’ lives, and the trial ended once all participants had passed away, the company said.
The trials tested whether people taking the drug would on average live significantly longer than those in the control group, it added.
Photo: CNA
The trials tested for overall survival time — the time the patient survives from the beginning of treatment — and progression-free survival time — the time the patient’s cancer does not worsen from the beginning of treatment, it said.
The median overall survival time for the 108 participants treated with SB05PC was 226 days, while their median progression-free survival time was 113 days.
Meanwhile, the median overall survival time of the 100 patients in the control group was 209 days, while their median progression-free survival time was 110 days, the drugmaker said.
“The difference between the two groups was not statistically significant,” Tim Lee (李志文), chairman of the drugmaker’s parent company Sinphar Pharmaceutical Co Ltd (杏輝醫藥), told a news conference in Taipei.
Other secondary gauges, such as disease control rate, objective response, rate and duration of response also did not show statistical significance, the company said.
The disease control rate averaged 59.38 percent in the treatment group, compared with 48.86 percent in the control group; the objective response rate was 11.46 percent in the treatment group, compared with 6.82 percent in the control group; and response to the drug averaged 4.1 months in the treatment group, compared with 5.6 months in the control group, it said.
SB05PC was developed as a second-line treatment to be combined with chemotherapy drug gemcitabine for patients who do not respond well to first-line drug Folfirinox, SynCore said.
Trail participants either received SB05PC in combination with gemcitabine, or only gemcitabine in the control group, it said.
Although no statistical significance, which would allow SynCore to seek approval for the treatment, was found, the trials were meaningful, as it would base the further development of SB05PC on the results, Lee said.
Phase 3 trials were conducted in seven countries — Taiwan, the US, France, Hungary, Israel, Russia and South Korea — and some populations seemed to react better to the drug, Lee said.
“It was a valuable experience, and we also learned how to be more exact in deciding the development direction of a new drug. This experience is an intangible asset,” Lee said.
SynCore has been developing SB05PC for six years, investing NT$2 billion (US$71.65 million) in the treatment, Lee said, adding that Sinphar funded the project with NT$1.77 billion.
After ending the project, Sinphar is expected to regain profitability, Lee said, aiming to post annual net profit of about NT$400 million.
SynCore reported a net loss of NT$159 million for the first six months of this year, while Sinphar reported net profit of NT$10.34 million, down 71 percent from a year earlier, Sinphar data showed.
SEMICONDUCTOR SERVICES: A company executive said that Taiwanese firms must think about how to participate in global supply chains and lift their competitiveness Taiwan Semiconductor Manufacturing Co (TSMC, 台積電) yesterday said it expects to launch its first multifunctional service center in Pingtung County in the middle of 2027, in a bid to foster a resilient high-tech facility construction ecosystem. TSMC broached the idea of creating a center two or three years ago when it started building new manufacturing capacity in the US and Japan, the company said. The center, dubbed an “ecosystem park,” would assist local manufacturing facility construction partners to upgrade their capabilities and secure more deals from other global chipmakers such as Intel Corp, Micron Technology Inc and Infineon Technologies AG, TSMC said. It
NO BREAKTHROUGH? More substantial ‘deliverables,’ such as tariff reductions, would likely be saved for a meeting between Trump and Xi later this year, a trade expert said China launched two probes targeting the US semiconductor sector on Saturday ahead of talks between the two nations in Spain this week on trade, national security and the ownership of social media platform TikTok. China’s Ministry of Commerce announced an anti-dumping investigation into certain analog integrated circuits (ICs) imported from the US. The investigation is to target some commodity interface ICs and gate driver ICs, which are commonly made by US companies such as Texas Instruments Inc and ON Semiconductor Corp. The ministry also announced an anti-discrimination probe into US measures against China’s chip sector. US measures such as export curbs and tariffs
The US on Friday penalized two Chinese firms that acquired US chipmaking equipment for China’s top chipmaker, Semiconductor Manufacturing International Corp (SMIC, 中芯國際), including them among 32 entities that were added to the US Department of Commerce’s restricted trade list, a US government posting showed. Twenty-three of the 32 are in China. GMC Semiconductor Technology (Wuxi) Co (吉姆西半導體科技) and Jicun Semiconductor Technology (Shanghai) Co (吉存半導體科技) were placed on the list, formally known as the Entity List, for acquiring equipment for SMIC Northern Integrated Circuit Manufacturing (Beijing) Corp (中芯北方積體電路) and Semiconductor Manufacturing International (Beijing) Corp (中芯北京), the US Federal Register posting said. The
India’s ban of online money-based games could drive addicts to unregulated apps and offshore platforms that pose new financial and social risks, fantasy-sports gaming experts say. Indian Prime Minister Narendra Modi’s government banned real-money online games late last month, citing financial losses and addiction, leading to a shutdown of many apps offering paid fantasy cricket, rummy and poker games. “Many will move to offshore platforms, because of the addictive nature — they will find alternate means to get that dopamine hit,” said Viren Hemrajani, a Mumbai-based fantasy cricket analyst. “It [also] leads to fraud and scams, because everything is now
RSS